Shares of biotechnology company CV Therapeutics Inc. (CVTX,Trade) slumped more than 20 percent on Wednesday after Morgan Stanley lowered its rating on the company and suggested its new treatment for angina, or chest pain, may need to carry a warning on its label.
Shares of Palo Alto, California-based CV Therapeutics dropped $4.91 to $19.49 in afternoon trading, reaching a new 52-week low earlier in the session
ganz schön nervös die Biotechs
Shares of Palo Alto, California-based CV Therapeutics dropped $4.91 to $19.49 in afternoon trading, reaching a new 52-week low earlier in the session
ganz schön nervös die Biotechs
Werbung